These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26961503)

  • 1. Pleotropic effects of leptin to reverse insulin resistance and diabetic ketoacidosis.
    Perry RJ; Petersen KF; Shulman GI
    Diabetologia; 2016 May; 59(5):933-7. PubMed ID: 26961503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of leptin in diabetes: metabolic effects.
    Meek TH; Morton GJ
    Diabetologia; 2016 May; 59(5):928-32. PubMed ID: 26969486
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renaissance of leptin for obesity therapy.
    Quarta C; Sánchez-Garrido MA; Tschöp MH; Clemmensen C
    Diabetologia; 2016 May; 59(5):920-7. PubMed ID: 26983921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism for leptin's acute insulin-independent effect to reverse diabetic ketoacidosis.
    Perry RJ; Peng L; Abulizi A; Kennedy L; Cline GW; Shulman GI
    J Clin Invest; 2017 Feb; 127(2):657-669. PubMed ID: 28112679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin reverses diabetes by suppression of the hypothalamic-pituitary-adrenal axis.
    Perry RJ; Zhang XM; Zhang D; Kumashiro N; Camporez JP; Cline GW; Rothman DL; Shulman GI
    Nat Med; 2014 Jul; 20(7):759-63. PubMed ID: 24929951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucagon: acute actions on hepatic metabolism.
    Miller RA; Birnbaum MJ
    Diabetologia; 2016 Jul; 59(7):1376-1381. PubMed ID: 27115415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glucagon is the key factor in the development of diabetes.
    Lee YH; Wang MY; Yu XX; Unger RH
    Diabetologia; 2016 Jul; 59(7):1372-1375. PubMed ID: 27115412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MST1: a promising therapeutic target to restore functional beta cell mass in diabetes.
    Ardestani A; Maedler K
    Diabetologia; 2016 Sep; 59(9):1843-9. PubMed ID: 27053234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipids and immunoinflammatory pathways of beta cell destruction.
    Imai Y; Dobrian AD; Morris MA; Taylor-Fishwick DA; Nadler JL
    Diabetologia; 2016 Apr; 59(4):673-8. PubMed ID: 26868492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How does leptin restore euglycemia in insulin-deficient diabetes?
    Oberlin D; Buettner C
    J Clin Invest; 2017 Feb; 127(2):450-453. PubMed ID: 28112680
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insulin increases serum leptin concentrations in children and adolescents with newly diagnosed type I diabetes mellitus with and without ketoacidosis.
    Flück CE; Kuhlmann BV; Mullis PE
    Diabetologia; 1999 Sep; 42(9):1067-70. PubMed ID: 10447517
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum levels of leptin and changes during the course of recovery from diabetic ketoacidosis.
    Nakamura T; Nagasaka S; Ishikawa S; Fujibayashi K; Kawakami A; Rokkaku K; Hayashi H; Saito T; Kusaka I; Higashiyama M; Saito T
    Diabetes Res Clin Pract; 1999 Oct; 46(1):57-63. PubMed ID: 10580617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
    Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple benefits of targeting inflammation in the treatment of type 2 diabetes.
    Donath MY
    Diabetologia; 2016 Apr; 59(4):679-82. PubMed ID: 26868493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leptin treatment confers clinical benefit at multiple stages of virally induced type 1 diabetes in BB rats.
    Kruger AJ; Yang C; Lipson KL; Pino SC; Leif JH; Hogan CM; Whalen BJ; Guberski DL; Lee Y; Unger RH; Greiner DL; Rossini AA; Bortell R
    Autoimmunity; 2011 Mar; 44(2):137-48. PubMed ID: 20695765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals.
    Moon HS; Dalamaga M; Kim SY; Polyzos SA; Hamnvik OP; Magkos F; Paruthi J; Mantzoros CS
    Endocr Rev; 2013 Jun; 34(3):377-412. PubMed ID: 23475416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gestational diabetes mellitus and long-term consequences for mother and offspring: a view from Denmark.
    Damm P; Houshmand-Oeregaard A; Kelstrup L; Lauenborg J; Mathiesen ER; Clausen TD
    Diabetologia; 2016 Jul; 59(7):1396-1399. PubMed ID: 27174368
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it worth treating gestational diabetes: if so, when and how?
    Vääräsmäki M
    Diabetologia; 2016 Jul; 59(7):1391-1395. PubMed ID: 27168136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.